Dyax Corp.  

(Public, NASDAQ:DYAX)   Watch this stock  
Find more results for DYAX
-0.20 (-0.84%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.06 - 24.52
52 week 9.19 - 30.55
Open 23.67
Vol / Avg. 700,347.00/926,985.00
Mkt cap 3.47B
P/E     -
Div/yield     -
EPS -0.13
Shares 146.36M
Beta 0.78
Inst. own 99%
Oct 26, 2015
Q3 2015 Dyax Corp Earnings Release (Estimated) Add to calendar
Sep 18, 2015
Dyax Corp at Morgan Stanley Healthcare Conference - 11:05AM EDT - Add to calendar
Aug 12, 2015
Dyax Corp at Wedbush PacGrow Healthcare Conference
Jul 29, 2015
Q2 2015 Dyax Corp Earnings Call
Jul 29, 2015
Q2 2015 Dyax Corp Earnings Release
Jun 1, 2015
Dyax Corp at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -31.89% -14.53%
Operating margin -22.39% -1.51%
EBITD margin - -0.45%
Return on average assets -10.56% -6.76%
Return on average equity -16.10% -17.98%
Employees 124 -
CDP Score - -


55 Network Dr
BURLINGTON, MA 01803-2756
United States - Map
+1-617-2505769 (Phone)
+1-617-2252501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Officers and directors

Henry E. Blair Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gustav A. Christensen President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
George V. Migausky Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Andrew D. Ashe Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Burt A. Adelman M.D. Chief Medical Officer, Executive Vice President - Research and Development
Age: 62
Bio & Compensation  - Reuters
Todd M Bazemore Executive Vice President and Chief Commercial Officer
Age: 44
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Abbie C. Celniker Ph.D Independent Director
Age: 56
Bio & Compensation  - Reuters
Ron Cohen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
James W. Fordyce Independent Director
Age: 72
Bio & Compensation  - Reuters